Can a newer drug protect heart health after kidney transplant?

NCT ID NCT06291077

Recruiting now Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at kidney transplant patients who take immunosuppressants to prevent organ rejection. It compares the effects of belatacept, a newer drug, against standard anticalcineurins on blood vessel function. The goal is to see if belatacept improves vascular health and reduces heart risks. About 44 participants will be followed for 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Belatacept
What this could lead to: If successful, this could show that switching to belatacept improves blood vessel function, potentially reducing heart risks in kidney transplant patients.
What could go wrong: This is a small, early-phase study with only 44 participants, so results may not apply broadly. Belatacept may not improve vessel function as hoped, and patients still need lifelong immunosuppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY DISEASES

Contacts and locations

Locations

CHU de ROUEN
RECRUITING

Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.